Heat shock protein 70 (HSP70) is a molecular chaperone that plays a critical role in protein homeostasis (proteostasis). In neurodegenerative diseases, the proteostasis network becomes overwhelmed, leading to accumulation of misfolded and aggregated proteins including amyloid-beta, tau, alpha-synuclein, and TDP-43. Inducing HSP70 expression represents a therapeutic strategy to enhance the cell's natural capacity to refold and clear toxic protein aggregates, addressing a fundamental mechanism common to multiple neurodegenerative disorders.
The proteostasis network, comprising molecular chaperones, the ubiquitin-proteasome system, and autophagy, declines with age and is further compromised in neurodegenerative diseases[1]. Key pathological features:
Primary Mechanism: Administer small molecule HSP70 inducers to increase expression of HSP70 and co-chaperones, enhancing the cell's capacity to refold misfolded proteins and target aggregates for clearance[2].
Secondary Mechanism: HSP70 induction also activates autophagy through TFEB (Transcription Factor EB), promoting clearance of protein aggregates via the lysosomal pathway[3].
Tertiary Mechanism: HSP70 has direct anti-apoptotic effects and can reduce neuroinflammation by modulating glial cell activation.
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 7 | Multiple HSP70 inducers in development; mechanism well-validated but clinical translation ongoing |
| Mechanistic Rationale | 9 | Strong preclinical data across multiple models; HSP70 is central to proteostasis |
| Addresses Root Cause | 8 | Enhances protein folding and clearance; addresses upstream pathogenesis |
| Delivery Feasibility | 7 | CNS penetration challenging but achievable with optimized compounds |
| Safety Plausibility | 8 | HSP70 induction is physiologically tolerated; natural protective response |
| Combinability | 9 | Synergistic with proteasome inhibitors, autophagy inducers, and anti-aggregation approaches |
| Biomarker Availability | 7 | HSP70 levels in CSF, autophagy markers, aggregate burden can be monitored |
| De-risking Path | 7 | Multiple compound classes available; clear mechanism-based endpoints |
| Multi-disease Potential | 9 | Strong rationale across AD, PD, ALS, FTD, Huntington's disease |
| Patient Impact | 7 | Addresses fundamental mechanism; potential for broad benefit |
Total Score: 72/100
Natural compounds:
Synthetic compounds:
| Phase | Timeline | Cost | Key Milestones |
|---|---|---|---|
| Lead optimization | 18 months | $8-15M | Identify clinical candidate |
| Phase 1/2a | 18 months | $20-35M | Safety, target engagement |
| Phase 3 | 24 months | $50-80M | Registrational trial |
| Total | 60 months | $78-130M |
Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. Science. 2008. ↩︎
Westerheide SD, Morimoto RI. Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem. 2005. ↩︎
Zhang J, Wang J, Pang L, et al. HSP70 induces autophagy via TFEB-mediated lysosomal biogenesis. Cell Death Dis. 2020. ↩︎
Neef DW, Turski ML, Thiele DJ. Modulation of the heat shock molecular chaperone HSF1. Cold Spring Harb Perspect Biol. 2010. ↩︎
Kaliannan O, Gandhi A, Alevras I, et al. Arimoclomol, a heat shock protein co-inducer, for the treatment of neurodegenerative diseases. Expert Opin Investig Drugs. 2019. ↩︎ ↩︎
Hoshino T, Murao N, Namba T, et al. Suppression of Alzheimer's disease-related phenotypes by geranylgeranylacetone in mice. PLoS One. 2011. ↩︎
Zhou Q, Yen A, Ryman SH, et al. Heat shock proteins protect dopaminergic neurons from alpha-synuclein toxicity. Neurobiol Dis. 2013. ↩︎